Xenon Pharmaceuticals (NASDAQ:XENE) Announces Earnings Results

Xenon Pharmaceuticals (NASDAQ:XENE) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05, Zacks reports.

Xenon Pharmaceuticals Stock Down 3.4 %

NASDAQ XENE opened at $37.02 on Friday. The firm has a market cap of $2.82 billion, a P/E ratio of -13.13 and a beta of 1.20. The company’s 50 day moving average is $39.27 and its 200-day moving average is $40.30. Xenon Pharmaceuticals has a 12-month low of $33.27 and a 12-month high of $50.99.

Analyst Upgrades and Downgrades

XENE has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $57.38.

Insider Buying and Selling

In related news, CEO Ian Mortimer sold 22,468 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,492 shares of company stock valued at $2,334,969. Company insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.